MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
17.95
-0.25 (-1.37%)
At close: Nov 26, 2025, 4:00 PM EST
17.99
+0.04 (0.22%)
After-hours: Nov 26, 2025, 4:10 PM EST
MediWound Revenue
MediWound had revenue of $5.43M in the quarter ending September 30, 2025, with 24.66% growth. This brings the company's revenue in the last twelve months to $20.93M, up 6.15% year-over-year. In the year 2024, MediWound had annual revenue of $20.22M with 8.22% growth.
Revenue (ttm)
$20.93M
Revenue Growth
+6.15%
P/S Ratio
9.34
Revenue / Employee
$188,577
Employees
111
Market Cap
230.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MDWD News
- 7 days ago - MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - MediWound to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid® - GlobeNewsWire
- 2 months ago - MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares - GlobeNewsWire
- 2 months ago - MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia - GlobeNewsWire
- 3 months ago - MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress - GlobeNewsWire
- 3 months ago - MediWound Is A Buy Opportunity On The Dip - Seeking Alpha